Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
26 avr. 2021 08h00 HE
|
Zosano Pharma Corporation
– Company Establishes Agreement with Worldwide Clinical Trials to Conduct PK Study – – Anticipates initiating PK Study in June and Completion in Q3 2021 – FREMONT, Calif., April 26,...
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
11 mars 2021 16h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and...
Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive...
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
22 févr. 2021 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official...
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines
01 févr. 2021 08h30 HE
|
Zosano Pharma Corporation
Review of data from the ZOTRIP trial suggest that Qtrypta showed therapeutic gain at 30 minutes consistent with recently published criteria for evaluating early onset of actionAll Qtrypta patients who...
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
01 févr. 2021 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company completed its Type A meeting...
Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application
04 janv. 2021 16h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on December 30, 2020 the company...
Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference
04 janv. 2021 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive...
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16 nov. 2020 18h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of the Board...
Zosano Pharma Reports Third Quarter 2020 Financial Results
13 nov. 2020 16h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter...